- Home
- GOSS vs ANAB Comparison
GOSS vs ANAB Comparison
Compare GOSS & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- ANAB
- Stock Information
- Founded
- GOSS 2015
- ANAB 2005
- Country
- GOSS United States
- ANAB United States
- Employees
- GOSS N/A
- ANAB N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- GOSS Health Care
- ANAB Health Care
- Exchange
- GOSS Nasdaq
- ANAB Nasdaq
- Market Cap
- GOSS 586.6M
- ANAB 630.2M
- IPO Year
- GOSS 2019
- ANAB 2017
- Fundamental
- Price
- GOSS $2.94
- ANAB $21.90
- Analyst Decision
- GOSS Strong Buy
- ANAB Buy
- Analyst Count
- GOSS 4
- ANAB 10
- Target Price
- GOSS $8.50
- ANAB $48.00
- AVG Volume (30 Days)
- GOSS 3.3M
- ANAB 465.1K
- Earning Date
- GOSS 11-06-2025
- ANAB 11-04-2025
- Dividend Yield
- GOSS N/A
- ANAB N/A
- EPS Growth
- GOSS N/A
- ANAB N/A
- EPS
- GOSS N/A
- ANAB N/A
- Revenue
- GOSS $40,237,000.00
- ANAB $123,164,000.00
- Revenue This Year
- GOSS N/A
- ANAB $11.22
- Revenue Next Year
- GOSS $30.65
- ANAB $8.35
- P/E Ratio
- GOSS N/A
- ANAB N/A
- Revenue Growth
- GOSS N/A
- ANAB 304.17
- 52 Week Low
- GOSS $0.66
- ANAB $12.21
- 52 Week High
- GOSS $2.98
- ANAB $40.70
- Technical
- Relative Strength Index (RSI)
- GOSS 76.74
- ANAB 52.43
- Support Level
- GOSS $2.41
- ANAB $19.86
- Resistance Level
- GOSS $2.71
- ANAB $22.98
- Average True Range (ATR)
- GOSS 0.19
- ANAB 1.00
- MACD
- GOSS 0.04
- ANAB 0.35
- Stochastic Oscillator
- GOSS 96.37
- ANAB 69.14
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).